Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab Concentration in Mature Breast Milk (BE CARING)
NCT06888193Phase 1Recruiting
- Sponsor
- UCB
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of bimekizumab in plaque psoriasis, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and 1 more, sponsored by UCB. Primary endpoint: Concentration of bimekizumab in the breast milk at Day 57. Started Nov 2025; status: recruiting.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)axial spondyloarthritis (axSpA)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06888193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888193.